All News

vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Evidence-Based Guidelines for EGPA

d Jack Cush, MD

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally. This adult disorder has a mean age at diagnosis of nearly 50 years and affects both sexes equally, presenting with pulmonary symptoms (asthma), eosinophilia and granulomatous or vasculitic involvement of several organs. A multidisciplinary, multinational European group has developed evidence-based, guidelines for the diagnosis and management of EGPA, intended to include recent advances.

Read Article
pain.jpg

RELIEF Trial: Sublingual Cyclobenzaprine in Fibromyalgia

d MedPage Today

Fibromyalgia patients hoping to see a more effective and convenient formulation of cyclobenzaprine at their local pharmacies must wait for an ongoing phase III trial -- the product's third -- to finish, as the first two delivered mixed results.

Read Article
PSS.scleroderma.arthritis.contractures

Juvenile and Adult-onset Scleroderma Differ

d Jack Cush, MD

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.  

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

ICYMI: Our old friend, hydroxychloroquine

d Eric Dein, MD

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Read Article
Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis Analysis of patient data from five Nordic registries shows that the uptake of newer b/tsDMARDs in PsA was mainly in biologic-experienced patients. https://t.co/SP9ZKGvM0J https://t.co/1tfSiWHYfl

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA approves a NGF inhbitor bedinvetmab (Librela) to treat osteoarthritis in Dogs!. Recently FDA approved NGF inhibitor cats w/ OA --- Yet 4 different NGF inhibitors failed in their development for human OA - are cats & dogs treated better than us? https://t.co/Tbca0PiEL2 https://t.co/Y7mViSa5J4

Links:

Dr. John Cush RheumNow ( View Tweet)
One in Ten is Bad! This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease! https://t.co/5SXPotfhs0 https://t.co/jXwsWoltsy

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Giving Good Care in Diversity takes Time Dr. Yvonne Sherrer and second-year fellow Dr. Corin Agoris discuss a case where extended time led to improved patient outcomes. https://t.co/NRHBwHLqSi https://t.co/nj8eaGiU50

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Meetings should be like Oktoberfest https://t.co/pZGOYXINir https://t.co/RIXmpRztaL

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Modern Management of PsA Faculty Panel Q&A , https://t.co/WIESJSL8WF https://t.co/0k7FyYkFtc

Links:

Dr. John Cush RheumNow ( View Tweet)
Chinese study of 4091 SLE pts, 3% (106) dx w/ osteonecrosis (AVN). AVN risk factors included: - SLE onset age ≤ 30 (HR 1.6) - Arthritis (HR 1.6) - Organ damage (HR 2.6) - RNP+ (HR 1.7) - High steroid doses (HR 1.7) https://t.co/DnqhEIWztY https://t.co/aP0uh0oh1x

Links:

Dr. John Cush RheumNow ( View Tweet)
Proposed AOSD criteria: 80 AOSD vs 60 autoimmune pts: \Nneed 7 points = AOSD dx (sensitivity 92%, specificity 93%, AUC 93%): - typical rash 3 pts - fever ≥ 39°C 3 pts - pharyngitis 2 pts - arthritis 2 pts - glycosylated ferritin≤ 20% 1 pt https://t.co/iLUryBVa7C https://t.co/HTWgAucBIm

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 EULAR Recommendations on Screening and Prophylaxis for Opportunistic Infections Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with AIIRD, that may be immunocompromised. https://t.co/eAN3X3kAHV https://t.co/qpFc7hlG7u

Links:

Dr. John Cush RheumNow ( View Tweet)
Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG). https://t.co/tYOwsNaiGy https://t.co/Bpfft4J9MB

Links:

Dr. John Cush RheumNow ( View Tweet)
Heart to Heart: Cardiovascular Risk in RA Tune in as Dr. Christina Charles-Schoeman and Dr. Roy Fleischmann discuss how to help mitigate CVD risk in patients with RA in the latest therapeutic update sponsored by AbbVie US Medical Affairs. https://t.co/52g6cnI5Wi https://t.co/E87OUHWFib

Links:

Dr. John Cush RheumNow ( View Tweet)
Comprehensive full read review of Cutaneous Lupus Erythematosus - pathogenesis, pathology and treatment options. https://t.co/J7C0511kBJ https://t.co/ILhcpeT5cx

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy in PsA RheumNow Live 2023: Christina Chambers, PhD, MPH, University of California, San Diego School of Medicine https://t.co/QR0Mb7F1x3 https://t.co/rj6HtoUTpE

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in Psoriasis and PsA RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine https://t.co/eVwQ6ITzD7 https://t.co/GZxVx77aV1

Links:

Dr. John Cush RheumNow ( View Tweet)
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported. https://t.co/DMsjFzmjPn https://t.co/X1fg9ylo7g

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 481 incident RA: - no risk of RA w/ tea, alcohol & sugar-soft drinks - Incr RA risk seen w/ coffee [≥4 vs ≤1cup, HR=1.24;p=0.04] & diet drinks [HR=1.66;never-smokers] - Reduced RA risk w/ mod EtOH (ever-smokers;HR=0.63) & wine (seropos RA) https://t.co/RQFpxXUT11 https://t.co/ew2imYMLnJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×